One team, one vision
At the core, AMYRA consists of a complimentary team of individuals with wide-reaching strengths and competencies. Bound together by trustworthiness and a common vision, each team member is an invaluable part of realising AMYRA’s goal of positively impacting the lives of millions of people around the globe.
Team
Dr. Werner Tschollar
CEO
Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.
Priv. Doz. Dr. Ghazaleh Gouya
CMO
Ghazaleh is responsible for clinical development. She has 20+ years experience in clinical research and drug development. She held a senior position in a worldwide operating contract research organisation. She is an MD and is board certified in internal medicine, cardiology and clinical pharmacology.
Marcel Gremaud
CFO
Marcel has 34 years of experience as an auditor, controller and CFO for Ernest & Young (EY) and Santhera. He is now the Group Financial Controller of a publicly traded company and an audit manager at EY.
Dr. Silvia Tietz
Director Scientific Affairs
Silvia is responsible for scientific affairs, the preclinical program including the ex vivo / in vitro POC studies and CMC including formulation development. She holds a PhD in biology and has 10+ years research experience in the field of autoimmune diseases. As a neuroimmunologist she is an expert in T cell biology and tissue barrier integrity.
Ralph Jelinski
Head Business Development
Ralph has 20+ years of experience in the banking industry, specifically in
wealth planning, distribution and private equity. He has also served 6 years as CEO/COO in a private company.
Board of Directors
Dr. Werner Tschollar
Chairman of the Board of Directors
Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.
Dr. Thomas Zehnder
Member of the Board of Directors
Thomas is a co-founder of AMYRA. He has over 20 years of experience in the medtech and healthcare industries as both a senior healthcare executive and an entrepreneur. He holds a MSc from the Swiss Institute of Technology (ETH) in Zurich and a doctorate in Business Administration / Technology Management from the University of St. Gall HSG.
Douglas Gunthardt
Member of the Board of Directors
Douglas has 20 years of international leadership experience with both American high-tech and Swiss life-science corporations, including 8 years as CEO of Siegfried. He is active on boards of Ricola and XiMo, providing expertise on finance and risk management issues.
Scientific Advisory Board
Prof. Dr. Werner Weitschies
Chief Scien fic Advisor
Werner is an expert in pharmaceutical technologies, gastro-intestinal models, formulation development and testing. Since 2003, he he is a Professor of Biopharmaceutics (C4) at the Ernst-Moritz-Arndt-University of Greifswald, Germany. He has published more than 200 peer reviewed articles and 30 patents.
Prof. Dr. Dr. Gerhard Rogler
Member of Advisory Board
Gerhard is a clinical expert for celiac disease. He is scientific advisor to the Swiss Celiac Disease Society. He serves as the Chairman of the Scientific Advisory Board of the University of Zurich and Professor of Gastroenterology and Hematology and Consultant Gastroenterologist at the Zurich University Hospital, Switzerland. He has authored about 200 original peer-reviewed articles.
Prof. Dr. Knut E.A. Lundin
Member of Advisory Board
Knut is Professor of Medicine and Head of Clinical Education at the University of Oslo, Norway. He is also a consultant gastroenterologist at the endoscopy unit at Oslo University Hospital, Rikshospitalet and he is one of the leading European clinicians in the field of celiac disease. Professor Lundin currently serves as the president of the European Society for the Study of Celiac Disease.
Prof. Frits Koning
Member of Advisory Board
Frits is a Professor of Immunology at the Department of Immunohematology and Blood Transfusion at Leiden University. He also serves as Chairman of the Scientific Advisory Board of LUMC (Leiden University Medical Center). Furthermore, he served as the Director of the Celiac Disease Consortium 2004 – 2014.
Prof. Dr. Rolf Bass
Member of Advisory Board
Rolf is an expert for regulatory affairs. He set up the new Department for European and International Business of the German Federal Institute for Drugs and Medical Devices (BfArM). Today, he is a visiting Professor for Pharmaceutical Medicine, University of Basel, Switzerland where he is responsible for the postgraduate Master curricula for Regulatory Affairs within Pharmaceutical Medicine.
Dr. Gerd Bode
Member of Advisory Board
Gerd is an expert for pre-clinical and clinical drug development. From 2000 to 2005 Gerd Bode was advisor for and lecturer in toxicology at the WHO. Since 2005 he has been a lecturer at several universities and scientific advisory to numerous large and small pharma companies.
